TY - JOUR
T1 - E.U. paediatric MOG consortium consensus
T2 - Part 3 – Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders
AU - E.U. paediatric MOG consortium
AU - Armangue, Thaís
AU - Capobianco, Marco
AU - de Chalus, Aliénor
AU - Laetitia, Giorgi
AU - Deiva, Kumaran
AU - Bruijstens, Arlette L.
AU - Wendel, Eva Maria
AU - Lechner, Christian
AU - Bartels, Frederik
AU - Finke, Carsten
AU - Breu, Markus
AU - Flet-Berliac, Lorraine
AU - Adamsbaum, Catherine
AU - Hacohen, Yael
AU - Hemingway, Cheryl
AU - Wassmer, Evangeline
AU - Lim, Ming
AU - Baumann, Matthias
AU - Wickström, Ronny
AU - Rostasy, Kevin
AU - Neuteboom, Rinze F.
N1 - Funding Information:
This study was supported in part by the Marato TV3 Foundation ( 20141830 ) and Torrons Vicens Foundation ( PFNR0144 to TA).
Publisher Copyright:
© 2020 European Paediatric Neurology Society
PY - 2020/11
Y1 - 2020/11
N2 - A first episode of acquired demyelinating disorder (ADS) in children is a diagnostic challenge as different diseases can express similar clinical features. Recently, antibodies against myelin oligodendrocyte glycoprotein (MOG) have emerged as a new ADS biomarker, which clearly allow the identification of monophasic and relapsing ADS forms different from MS predominantly in children. Due to the novelty of this antibody there are still challenges and controversies about its pathogenicity and best technique to detect it. In this manuscript we will discuss the recommendations and caveats on MOG antibody assays, role in the pathogenesis, and additionally discuss the usefulness of other potential new biomarkers in MOG-antibody associated disorders (MOGAD).
AB - A first episode of acquired demyelinating disorder (ADS) in children is a diagnostic challenge as different diseases can express similar clinical features. Recently, antibodies against myelin oligodendrocyte glycoprotein (MOG) have emerged as a new ADS biomarker, which clearly allow the identification of monophasic and relapsing ADS forms different from MS predominantly in children. Due to the novelty of this antibody there are still challenges and controversies about its pathogenicity and best technique to detect it. In this manuscript we will discuss the recommendations and caveats on MOG antibody assays, role in the pathogenesis, and additionally discuss the usefulness of other potential new biomarkers in MOG-antibody associated disorders (MOGAD).
UR - http://www.scopus.com/inward/record.url?scp=85096091493&partnerID=8YFLogxK
U2 - 10.1016/j.ejpn.2020.11.001
DO - 10.1016/j.ejpn.2020.11.001
M3 - Review article
C2 - 33191096
AN - SCOPUS:85096091493
SN - 1090-3798
VL - 29
SP - 22
EP - 31
JO - European Journal of Paediatric Neurology
JF - European Journal of Paediatric Neurology
ER -